REG - e-Therapeutics plc - Exercise of Options and Issue of Equity

E-TherapeuticsAnnouncement

28/03/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230328:nRSb5174Ua&default-theme=true

RNS Number : 5174U  e-Therapeutics plc  28 March 2023

 

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

EXERCISE OF OPTIONS AND ISSUE OF EQUITY

 

LONDON, UK, 28 March 2023 - e-therapeutics plc (AIM: ETX), the drug discovery
company, announces that it has allotted 500,000 new ordinary shares of 0.1p
each in the Company (the "New Ordinary Shares") following the exercise of
share options at 2.8p per New Ordinary Share by a former employee.

 

Application has been made to AIM for the admission of the New Ordinary Shares
to trading on AIM ("Admission") and Admission is expected to occur at 8:00
a.m. on or around 11 April 2023. The New Ordinary Shares will rank pari passu
in all respects with the Company's existing ordinary shares in issue.

 

Following Admission, the total number of ordinary shares in the Company with
voting rights in issue will be 582,659,332. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

 

For further information, please contact:

 

 

Enquiries:

 

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)20 4551 8888
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc www.etherapeutics.co.uk
(http://www.etherapeutics.co.uk)

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets, and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.  The Company
generates, prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.

 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
in several therapeutic areas including haematology, cardiovascular disease
and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEKZGZFDRDGFZM